Your browser doesn't support javascript.
loading
SEOM clinical guideline for the management of cutaneous melanoma (2020).
Majem, M; Manzano, J L; Marquez-Rodas, I; Mujika, K; Muñoz-Couselo, E; Pérez-Ruiz, E; de la Cruz-Merino, L; Espinosa, E; Gonzalez-Cao, M; Berrocal, A.
Afiliación
  • Majem M; Department of Medical Oncology, Hospital de la Santa Creu i Sant Pau, c/Sant Antoni Maria Claret 167, 08025, Barcelona, Spain. mmajem@santpau.cat.
  • Manzano JL; Department of Medical Oncology, H. Germans Trias i Pujol, Catalan Institute of Oncology, ICO-Badalona, Badalona, Spain.
  • Marquez-Rodas I; Department of Medical Oncology, Instituto de Investigación Sanitaria Gregorio Marañón and CIBERONC, Madrid, Spain.
  • Mujika K; Department of Medical Oncology, UGC de Oncología de Gipuzkoa, OSI Donostialdea-Onkologikoa, Guipúzcoa, Spain.
  • Muñoz-Couselo E; Department of Medical Oncology, Vall d'Hebron Institute of Oncology (VHIO), Hospital Vall d'Hebron Barcelona, Barcelona, Spain.
  • Pérez-Ruiz E; Department of Medical Oncology, Hospital Costa del Sol and UGC Oncol, Instituto de Investigación Biomédica de Málaga (IBIMA), Hospital Universitario Regional Virgen Victoria, Málaga, Spain.
  • de la Cruz-Merino L; Department of Medical Oncology, Hospital Universitario Virgen Macarena, Seville, Spain.
  • Espinosa E; Medicine Department, Universidad de Sevilla, Seville, Spain.
  • Gonzalez-Cao M; Department of Medical Oncology, Hospital Universitario La Paz, CIBERONC, Madrid, Spain.
  • Berrocal A; Oncology Department (IOR), Hospital Dexeus, Barcelona, Spain.
Clin Transl Oncol ; 23(5): 948-960, 2021 May.
Article en En | MEDLINE | ID: mdl-33651321
Melanoma affects about 6000 patients a year in Spain. A group of medical oncologists from Spanish Society of Medical Oncology (SEOM) and Spanish Multidisciplinary Melanoma Group (GEM) has designed these guidelines to homogenize the management of these patients. The diagnosis must be histological and determination of BRAF status has to be performed in patients with stage ≥ III. Stage I-III resectable melanomas will be treated surgically. In patients with stage III melanoma, adjuvant treatment with immunotherapy or targeted therapy is also recommended. Patients with unresectable or metastatic melanoma will receive treatment with immunotherapy or targeted therapy, the optimal sequence of these treatments remains unclear. Brain metastases require a separate consideration, since, in addition to systemic treatment, they may require local treatment. Patients must be followed up closely to receive or change treatment as soon as their previous clinical condition changes, since multiple therapeutic options are available.
Asunto(s)
Palabras clave
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Neoplasias Cutáneas / Melanoma Tipo de estudio: Diagnostic_studies / Guideline / Observational_studies / Prognostic_studies / Risk_factors_studies Límite: Humans País/Región como asunto: Europa Idioma: En Revista: Clin Transl Oncol Año: 2021 Tipo del documento: Article País de afiliación: España Pais de publicación: Italia
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Neoplasias Cutáneas / Melanoma Tipo de estudio: Diagnostic_studies / Guideline / Observational_studies / Prognostic_studies / Risk_factors_studies Límite: Humans País/Región como asunto: Europa Idioma: En Revista: Clin Transl Oncol Año: 2021 Tipo del documento: Article País de afiliación: España Pais de publicación: Italia